Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 7, 2013, Pages 537-548

  Morcos, Peter N ^a   Zhang, Xiaoping ^a   McIntyre, Christine ^b   Bittner, Beate ^c   Rowell, Lucy ^b   Hussain, Zubair ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Halozyme; Pharmacodynamic; Pharmacokinetic; Rheumatoid arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RECOMBINANT HYALURONIDASE; TOCILIZUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUTH ULCER; NEUTROPHIL COUNT; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG INTERACTIONS; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; INFLAMMATION MEDIATORS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84880240350     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201847     Document Type: Article

References (28)

1. Aletaha D, Smolen J. [Rheumatoid arthritis. Target outcome for treatment]. Z Rheumatol. 2009; 68: 10-15. CrossRef PubMed
2. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum. 1999; 42: 415-420. CrossRef PubMed (Pubitemid 29136087)
3. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; 7: CD008331. PubMed
4. Badley EM, Lee J, Wood PH. Patterns of disability related to joint involvement in rheumatoid arthritis. Rheumatol Rehabil. 1979; 18: 105-109. CrossRef PubMed (Pubitemid 9194862)
5. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scand J Rheumatol. 2005; 34: 333-341. CrossRef PubMed (Pubitemid 41545905)
6. Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol. 1992; 19: 1906-1911. PubMed (Pubitemid 23018522)
7. Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, Simon LS, Weaver AL. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol Suppl. 2008; 81: 4-30. PubMed
8. Chen YF, Jobanputra P, Barton P, Bryan S, Fry- Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008; 12: 1-278. PubMed
9. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin- Mola E, Nielsen H, Silman A, Smolen J, Yazici H. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66: 34-45. CrossRef PubMed (Pubitemid 46044858)
10. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343: 1586-1593. CrossRef PubMed (Pubitemid 32162981)
11. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988; 18: 1797-1801. CrossRef PubMed (Pubitemid 19011590)
12. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988; 31: 784-788. CrossRef PubMed
13. Madhok R, Beaton A, Smith J, Watson J, Sturrock R, Capell HA. The effect of second line drugs on serum interleukin 6 levels in rheumatoid arthritis. Arthritis Rheum. 1990; 33: S154.
14. Actemra® (tocilizumab injection, for intravenous infusion). South San Francisco, CA: Genentech, Inc.; 2011.
15. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006; 2: 619-626. CrossRef PubMed (Pubitemid 44650950)
16. RoActemra 20 mg/ml concentrate for solution for infusion SPC. Welwyn Garden City, UK: Roche Products Limited; 2011.
17. Actemra® for intravenous infusion. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; 2009.
18. Baxter Healthcare Corporation. HYLENEX recombinant (hyaluronidase human injection). Deerfield, IL: Baxter Healthcare Corporation; 2008.
19. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006; 114: 230-241. CrossRef PubMed (Pubitemid 44291844)
20. Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004; 93: 2184-2204. CrossRef PubMed (Pubitemid 39129617)
21. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84: 548-558. CrossRef PubMed
22. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11: 81-88. Cross- Ref PubMed (Pubitemid 43227856)
23. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010; 50: 754-766. CrossRef PubMed
24. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112: 3959-3964. CrossRef PubMed
25. Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol. 2011; 4: 539-558. CrossRef PubMed
26. Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, Aarden LA, van Rijswijk MH. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta. 1991; 1091: 405-408. CrossRef PubMed
27. Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol. 1988; 17: 469-474. CrossRef PubMed (Pubitemid 19068600)
28. Georgy A, Zhang X, Anzures-Cabrera J, Foley- Comer A. A clinical study to assess the pharmacokinetics and pharmacodynamics of tocilizumab after single-dose administration by subcutaneous and intravenous routes to healthy subjects. Poster ID: PII-65. American Society for Clinical Pharmacology and Therapeutics Annual Meeting. 2010; March 17 - 20; Atlanta, Georgia.